On Tuesday, Dr Reddy’s Laboratories Ltd revealed that it is among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, facing an antitrust lawsuit in the United States. The company disclosed in a regulatory filing that a complaint, filed on November 18, 2022, in the District of New Jersey, names it and other generic pharmaceutical firms as defendants.
According to Dr Reddy’s Laboratories, the complaint, representing a class of indirect purchasers, alleges violations of federal and state antitrust laws, along with other state laws. The claims assert that the defendants, through settlements of patent litigation, unlawfully restricted competition and maintained a collective monopoly in the sale of brand and generic Revlimid.
Revlimid, a prescription medicine, is utilized to treat adults with multiple myeloma (MM), either in combination with dexamethasone or as maintenance treatment after a specific type of stem cell transplant using the individual’s own stem cells.
Dr Reddy’s Laboratories stated that the complaint contends that the challenged agreements inappropriately delayed generic entry until 2022 and then restricted generic competition through 2026. The complaint seeks damages for alleged overpayments and equitable relief.
The company emphasized its strong stance against the allegations, asserting that they lack merit, and it intends to vigorously defend against the litigation.
